• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Rises 2%; Tesla Shares Plunge After Downbeat Results

    1/25/24 1:08:22 PM ET
    $AKTS
    $INBS
    $LVTX
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $AKTS alert in real time by email

    U.S. stocks traded slightly higher midway through trading, with the Nasdaq Composite gaining around 0.2% on Thursday.

    The Dow traded up 0.06% to 37,829.32 while the NASDAQ rose 0.22% to 15,515.62. The S&P 500 also rose, gaining, 0.26% to 4,881.28.

    Check This Out: How To Earn $500 A Month From Capital One Financial Ahead Of Its Q4 Earnings Report

     

    Leading and Lagging Sectors

     

    Communication services shares rose by 1.5% on Thursday.

    In trading on Thursday, consumer discretionary shares fell by 1.4%.

     

    Top Headline

     

    Tesla, Inc. (NASDAQ:TSLA) shares dipped more than 12% on Thursday after the company reported worse-than-expected fourth-quarter financial results.

    Tesla reported fourth-quarter revenue of $25.17 billion, which was up 3% year-over-year. The revenue missed a Street consensus estimate of $25.62 billion, according to data from Benzinga Pro. The company reported earnings per share of 71 cents, which missed a Street consensus estimate of 74 cents per share.

     

    Equities Trading UP

     

    Vera Therapeutics, Inc. (NASDAQ:VERA) shares shot up 40% to $23.87 after the company announced 72-week data from the OLE period of its Phase 2b ORIGIN clinical trial. Also, Oppenheimer initiated coverage on the stock with an Outperform rating and announced a $26 price target.

    Shares of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) got a boost, surging 120% to $4.5150 after the company announced the completion of the safety tolerability evaluation in its Phase 1b trial of Next Generation Capecitabine.

    LAVA Therapeutics N.V. (NASDAQ:LVTX) shares were also up, gaining 38% to $2.1401 after the company announced a clinical trial collaboration and supply agreement with Merck & Co. to evaluate LAVA-1207 in conbination with KEYTRUDA.

     

    Equities Trading DOWN

     

    RedHill Biopharma Ltd. (NASDAQ:RDHL) shares dropped 47% to $0.5680 after the company announced an $8 million registered direct offering.

    Shares of Akoustis Technologies, Inc. (NASDAQ:AKTS) were down 23% to $0.5401 after the company announced pricing of a public offering of $10 million of common stock.

    Intelligent Bio Solutions Inc. (NASDAQ:INBS) was down, falling 20% to $0.2354.
    Intelligent Bio Solutions reported a 1-for-12 reverse stock split.

    Also Check This Out: Visa Gears Up For Q4 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

     

    Commodities

     

    In commodity news, oil traded up 2% to $76.60 while gold traded down 0.1% at $2,013.50.

    Silver traded down 0.15% to $22.855 on Thursday while copper fell 0.5% to $3.8670.

     

    Euro zone

     

    European shares were mostly higher today. The eurozone’s STOXX 600 rose 0.30%, London’s FTSE 100 rose 0.03% while Spain’s IBEX 35 Index fell 0.58% The German DAX rose 0.10% French CAC 40 rose 0.11% while Italy’s FTSE MIB Index fell 0.60%.

    The European Central Bank kept interest rates unchanged during its recent meeting. The Ifo Business Climate indicator for Germany declined to 85.2 in January versus a revised reading of 86.3 in the prior month. Producer prices in Spain fell by 6.3% year-over-year in December, while manufacturing climate indicator in France came in unchanged at 99 for January.

     

    Asia Pacific Markets

     

    Asian markets closed mostly higher on Thursday, with Japan’s Nikkei 225 gaining 0.03%, Hong Kong’s Hang Seng Index climbing 1.96% and China’s Shanghai Composite Index gaining 3.03%. India’s S&P BSE Sensex, meanwhile, fell 0.51%.

    Imports to Hong Kong jumped by 11.6% year-over-year to $446.3 billion in December, while exports from Hong Kong rose 11% year-over-year to $386.4 billion.

     

    Economics

     

    The US economy grew an annualized 3.3% in the fourth quarter, versus market estimates of a 2% rise, and compared to a 4.9% rate in the prior quarter.

    U.S. initial jobless claims increased by 25,000 to 214,000 in the week ending Jan. 20.

    The US trade deficit in goods narrowed to $88.5 billion in December versus a revised $89.3 billion in the prior month.

    The Chicago Fed National Activity Index declined to -0.15 in December versus a revised 0.01 in the previous month.

    Wholesale inventories in the U.S. increased by 0.4% month-over-month in December.

    New orders for manufactured durable goods in the U.S. came in unchanged for December.

    U.S. natural-gas supplies fell 326 billion cubic during the week ended Jan. 19, 2024, the EIA said.

    Now Read This: Jim Cramer: This Healthcare Stock Is 'Too Risky,' But Shares Jumped 64% Over Past Month

    Get the next $AKTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKTS
    $INBS
    $LVTX
    $PCSA

    CompanyDatePrice TargetRatingAnalyst
    Vera Therapeutics Inc.
    $VERA
    3/11/2026$88.00Peer Perform → Outperform
    Wolfe Research
    Aktis Oncology Inc.
    $AKTS
    3/9/2026$30.00Buy
    H.C. Wainwright
    Tesla Inc.
    $TSLA
    3/4/2026$460.00Buy
    BofA Securities
    Tesla Inc.
    $TSLA
    2/12/2026$550.00Buy
    Tigress Financial
    Aktis Oncology Inc.
    $AKTS
    2/3/2026$30.00Overweight
    Analyst
    Aktis Oncology Inc.
    $AKTS
    2/3/2026$34.00Buy
    BofA Securities
    Aktis Oncology Inc.
    $AKTS
    2/3/2026$31.00Outperform
    Leerink Partners
    Aktis Oncology Inc.
    $AKTS
    2/3/2026Buy
    TD Cowen
    More analyst ratings

    $AKTS
    $INBS
    $LVTX
    $PCSA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Vera Therapeutics upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Vera Therapeutics from Peer Perform to Outperform and set a new price target of $88.00

    3/11/26 8:30:17 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Aktis Oncology with a new price target

    H.C. Wainwright initiated coverage of Aktis Oncology with a rating of Buy and set a new price target of $30.00

    3/9/26 9:06:39 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities resumed coverage on Tesla with a new price target

    BofA Securities resumed coverage of Tesla with a rating of Buy and set a new price target of $460.00

    3/4/26 8:40:18 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    $AKTS
    $INBS
    $LVTX
    $PCSA
    SEC Filings

    View All

    Vera Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Vera Therapeutics, Inc. (0001831828) (Filer)

    3/9/26 5:01:12 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Tesla Inc.

    144 - Tesla, Inc. (0001318605) (Subject)

    3/6/26 5:42:03 PM ET
    $TSLA
    Auto Manufacturing
    Industrials

    SEC Form 6-K filed by Redhill Biopharma Ltd.

    6-K - RedHill Biopharma Ltd. (0001553846) (Filer)

    3/5/26 9:00:19 AM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    $INBS
    $LVTX
    $PCSA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Foley Todd converted options into 4,002,533 shares and bought $4,191,660 worth of shares (232,870 units at $18.00) (SEC Form 4)

    4 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/14/26 6:20:21 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Mpm Bioventures 2018, L.P. converted options into 8,805,578 shares and bought $20,029,986 worth of shares (1,112,777 units at $18.00) (SEC Form 4)

    4 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/14/26 6:19:26 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Gadicke Ansbert converted options into 8,805,578 shares and bought $20,029,986 worth of shares (1,112,777 units at $18.00) (SEC Form 4)

    4 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/14/26 6:17:54 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    $INBS
    $LVTX
    $PCSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on March 3, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 46,000 shares of Class A common stock and restricted stock units (RSUs) underlying 25,875 shares of Class A common stock to six (6) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock

    3/6/26 4:05:00 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics Appoints Christopher Hite to Board of Directors

    BRISBANE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christopher Hite, an accomplished executive with decades of corporate and financial strategy leadership experience in the biopharmaceutical sector, to Vera Therapeutics' Board of Directors. "It is a pleasure to welcome Chris to our Board of Directors at this exciting juncture in Vera Therapeutics' trajectory as we near the potential launch of our first-in-class dual BAFF/APRIL inhibitor for patients with IgA nephropathy," sa

    3/5/26 9:00:22 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight

    The H. pylori infection market is evolving as treatment strategies shift toward optimized, targeted combination therapies, including triple- and quadruple-drug regimens, bismuth-based therapies, and novel emerging therapies such as Rifasutenizol (TenNor Therapeutics), Linaprazan glurate (Cinclus Pharma), Tegoprazan (RQ-00000004) (RaQualia Pharma/HK inno.N/Sebela Pharmaceuticals), and others, driven by improved eradication rates and safety profiles.LAS VEGAS, March 4, 2026 /PRNewswire/ -- Recently published H. pylori Infections Market Insights report includes a comprehensive understanding of current treatment practices, H. pylori infections emerging drugs, market share of individual therapies

    3/4/26 5:46:00 PM ET
    $CPIX
    $PHAT
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    $INBS
    $LVTX
    $PCSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Taneja Vaibhav converted options into 6,538 shares and sold $899,077 worth of shares (2,264 units at $397.03), increasing direct ownership by 31% to 18,106 units (SEC Form 4)

    4 - Tesla, Inc. (0001318605) (Issuer)

    3/9/26 7:00:14 PM ET
    $TSLA
    Auto Manufacturing
    Industrials

    SEC Form 4 filed by Director Hite Christopher

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    3/9/26 4:49:21 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Hite Christopher

    3 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    3/9/26 4:47:13 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    $INBS
    $LVTX
    $PCSA
    Leadership Updates

    Live Leadership Updates

    View All

    Vera Therapeutics Appoints Christopher Hite to Board of Directors

    BRISBANE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christopher Hite, an accomplished executive with decades of corporate and financial strategy leadership experience in the biopharmaceutical sector, to Vera Therapeutics' Board of Directors. "It is a pleasure to welcome Chris to our Board of Directors at this exciting juncture in Vera Therapeutics' trajectory as we near the potential launch of our first-in-class dual BAFF/APRIL inhibitor for patients with IgA nephropathy," sa

    3/5/26 9:00:22 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer

    BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Matt Skelton to Chief Commercial Officer, effective immediately. Mr. Skelton joined Vera Therapeutics over a year ago as the Executive Vice President, Commercial. "We are pleased to welcome Matt to the executive team as we prepare for the potential commercial launch of atacicept for the treatment of IgA nephropathy," said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. "With his track record

    1/28/26 7:30:00 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scientists Pointing to Hidden Power Source That Could Reshape Future of AI

    This article has been disseminated on behalf of MAX Power Mining Corp. and may include a paid advertisement. AUSTIN, Texas, Dec. 03, 2025 (GLOBE NEWSWIRE) -- MiningNewsWire: Global electricity demand is reaching a pivotal turning point. The International Energy Agency (IEA) now projects that global data-center electricity use will almost double by 2030, with AI-focused facilities increasing their consumption more than four times over the same span — a trajectory pushing power grids in the United States, China, Europe, Southeast Asia and other regions to their limits. The bottleneck is no longer data throughput or semiconductor performance; the critical constraint has become electricity it

    12/3/25 8:30:00 AM ET
    $AMZN
    $AVGO
    $META
    Catalog/Specialty Distribution
    Consumer Discretionary
    Semiconductors
    Technology

    $AKTS
    $INBS
    $LVTX
    $PCSA
    Financials

    Live finance-specific insights

    View All

    Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year

    First half fiscal 2026 revenue surpasses $2 million, up 36% year-over-year  Reader sales more than double to 104% year-over-year for the second quarter, demonstrating razor-razorblade model momentum Gross profit margins for first half fiscal 2026 increased 10% year-over-year to 49%, reflecting improved operational efficiency Current assets balance of $12.17 million as of December 31, 2025, including $9.40 million receivable in connection with the private placement of securities that closed on January 2, 2026. NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, no

    2/12/26 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Tesla Fourth Quarter 2025 Production, Deliveries & Deployments

    In the fourth quarter, we produced over 434,000 vehicles, delivered over 418,000 vehicles and deployed 14.2 GWh of energy storage products – a record for deployments. Thank you to all of our customers, employees, suppliers, shareholders and supporters who helped us achieve these results. Q4 2025   Production Deliveries Subject to operating lease accounting Model 3/Y 422,652 406,585 3% Other Models 11,706 11,642 5% Total 434,358 418,227 3% 2025   Production Deliveries Model 3/Y 1,600,767 1,585,279 Other Models 53,900 50,850

    1/2/26 9:07:00 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    Intelligent Bio Solutions Reports Fiscal 2026 First Quarter Financial Results and Operational Highlights, Delivering Record Revenue Growth

    Record quarterly revenue of $1.11 million, an increase of 32% sequentially and 28% year-over-year, driven by consumable cartridge sales and customer base expansion Gross profit margins increased 690 basis points year-over-year to 46.6%, reflecting improved operational efficiency and greater revenue percentage from higher margin cartridge sales NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal first quarter ended September 30, 2025. The fiscal 2026 first

    11/12/25 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $AKTS
    $INBS
    $LVTX
    $PCSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Intelligent Bio Solutions Inc.

    SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 7:16:17 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Intelligent Bio Solutions Inc.

    SC 13G - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 4:31:30 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vera Therapeutics Inc.

    SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)

    11/14/24 4:10:28 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care